CRISM developed the first Canadian guideline for managing opioid use disorders. The guideline lays out the optimal strategies for the treatment of opioid addiction and recommends opioid agonist treatment with buprenorphine-naloxone as the preferred first-line treatment.
Recommendations at a glance
Recommendations cliniques
A synopsis of the Guideline was published in the Canadian Medical Association Journal (March 5, 2018): http://www.cmaj.ca/content/190/9/E247 or download the PDF.
CAMJ also produced a podcast, which you can listen to here